180918-68-7 Usage
General Description
Trecetilide is a chemical compound that belongs to the class of organophosphorus compounds, containing phosphorus in the form of P(III). It is a highly reactive and potentially toxic compound that can have various industrial applications, particularly in the field of chemical synthesis. Trecetilide is known for its ability to form strong covalent bonds with other elements, making it useful in the production of pesticides and herbicides. However, its toxicity and potential for environmental and human health risks make it a highly regulated and controlled substance. It is important to handle trecetilide with caution and in accordance with strict safety protocols.
Check Digit Verification of cas no
The CAS Registry Mumber 180918-68-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,0,9,1 and 8 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 180918-68:
(8*1)+(7*8)+(6*0)+(5*9)+(4*1)+(3*8)+(2*6)+(1*8)=157
157 % 10 = 7
So 180918-68-7 is a valid CAS Registry Number.
180918-68-7Relevant articles and documents
Chemistry development of a convergent route to trecetilide hemi-fumarate
Mackey, Sonja S.,Wu, Haifeng,Matison, Michael E.,Goble, Michael
, p. 174 - 178 (2012/12/24)
A novel, efficient, stereoselective synthetic route for N-(4-{4-[ethyl(6-fluoro-6-methylheptyl)amino]-1-(S)-hydroxybutyl}-phenyl) methanesulfonamide hemi-fumaric acid salt (trecetilide hemi-fumarate, Figure 1) has been developed. The process features a convergent approach, which assembles two key intermediates in the last step to form the final molecule, which is then isolated by pH-controlled extraction. The new route offers significant yield and purity advantages over the previous route. However, the solvent volume and cycle time were not fully optimized due to the termination of the project.
Antiarrhythmic methanesulfonamides
-
, (2008/06/13)
Methanesulfonamides are structurally depicted by Formula I' STR1 or its pharmacologically acceptable salts where R3 is a C1-7 alkyl substituted with C3-7 cycloalkyl, or a C1-10 alkyl substituted with one to eigh